Cyclophosphamide and VP 16-213 with autologous bone marrow transplantation. A dose escalation study
作者： P.E. Postmus , E.G.E. De Vries , H.G. De Vries-Hospers , R. Vriesendorp , G.W. Van Imhoff
DOI: 10.1016/0277-5379(84)90216-5
关键词: Marrow transplantation 、 Gastroenterology 、 Toxicity 、 Internal medicine 、 In patient 、 Dose escalation 、 Surgery 、 Cyclophosphamide 、 Ovarian cancer 、 Autologous bone 、 Mucositis 、 Medicine
摘要: In 13 patients with therapy-resistant solid tumors the feasibility of high-dose cyclophosphamide (7 g/m2) in combination increasing doses VP 16-213 autologous bone marrow transplantation was studied. Dose-limiting extramedullary toxicity appeared to be mucositis and occurred after 2.5 g/m2. Two toxic deaths were observed older than 55 yr. Responses seen eight out nine evaluable patients. ovarian cancer still have no signs disease progression 12+ months. High-dose can combined 1.5 g/m2 without important toxicity. Age is probably a limiting factor for this kind therapy.
core.ac.uk
narcis.nl参考文章(17)
Th. Wobbes, M. J. H. Slooff, D. Th. Sleyfer, N. H. Mulder, Vascular access for chemotherapy: results of a simple procedure Springer Netherlands. pp. 267- 270 ,(1983) , 10.1007/978-94-009-6592-8_46
John D Minna, A. V. Johnston, B. E. Fossieck, P. J. Creaven, M. H. Cohen, O. S. Selawry, C. L. Williams, L. E. Broder, Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer treatment reports. ,vol. 61, pp. 349- 354 ,(1977)
H E Skipper, L H Schmidt, A manual on quantitative drug evaluation in experimental tumor systems. I. Background, description of criteria, and presentation of quantitative therapeutic data on various classes of drugs obtained in diverse experimental tumor systems. Cancer chemotherapy reports. ,vol. 17, pp. 1- 143 ,(1962)
G. W. Imhoff, F. Arnaud, P. E. Postmus, N. H. Mulder, P. C. Das, C.Th. Smit Sibinga, Autologous cryopreserved platelets and prophylaxis of bleeding in autologous bone marrow transplantation Annals of Hematology. ,vol. 47, pp. 203- 209 ,(1983) , 10.1007/BF00320839
I SMITH, Autologous bone marrow rescue is unnecessary after very-high-dose cyclophosphamide. The Lancet. ,vol. 321, pp. 76- 77 ,(1983) , 10.1016/S0140-6736(83)91617-3
P. E. Postmus, N. H. Mulder, E. G. E. de Vries, M. van Luyn, M. R. Halie, Small cell lung cancer and the influence of chemotherapy on CFUcs in bone marrow Cancer. ,vol. 53, pp. 396- 400 ,(1984) , 10.1002/1097-0142(19840201)53:3<396::AID-CNCR2820530305>3.0.CO;2-3
J.J.M. Holthuis, F.M.G.M. Römkens, H.M. Pinedo, W.J. Van Oort, Plasma assay for the antineoplastic agent VP 16-213 (etoposide) using high-performance liquid chromatography with electrochemical detection. Journal of Pharmaceutical and Biomedical Analysis. ,vol. 1, pp. 89- 97 ,(1983) , 10.1016/0731-7085(83)80012-0
Dirk Th. Sleijfer, Nanno H. Mulder, Hilly G. de Vries-Hospers, Vaclav Fidler, Hendrik O. Nieweg, Dirk van der Waaij, Hendrik K.F. van Saene, Infection prevention in granulocytopenic patients by selective decontamination of the digestive tract European Journal of Cancer. ,vol. 16, pp. 859- 869 ,(1980) , 10.1016/0014-2964(80)90140-1
Emil Frei, George P. Canellos, Dose: A Critical Factor in Cancer Chemotherapy The American Journal of Medicine. ,vol. 69, pp. 585- 594 ,(1980) , 10.1016/0002-9343(80)90472-6
John S Gottdiener, Frederick R Appelbaum, Victor J Ferrans, Albert Deisseroth, John Ziegler, Cardiotoxicity Associated With High-Dose Cyclophosphamide Therapy Archives of Internal Medicine. ,vol. 141, pp. 758- 763 ,(1981) , 10.1001/ARCHINTE.1981.00340060066015